Bluebird bio

With our lentiviral-based gene therapy and gene editing capabilities, we have built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapies for cancer. Our clinical programs include Lenti-D™, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and LentiGlobin®, currently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of transfusion-dependent ß-thalassemia (also known as ß-thalassemia major); a single-center Phase 1/2 study in France (HGB-205) for the treatment of transfusion-dependent ß-thalassemia or severe sickle cell disease; and a separate U.S. Phase 1 study for the treatment of severe sickle cell disease (HGB-206). We also have ongoing preclinical CAR T immuno-oncology programs, as well as discovery research programs utilizing megaTAL/homing endonuclease gene editing technologies. Our gene therapy process involves extracting certain cell types from a patient, inserting genetic material into the patient’s own cells and then re-infusing the gene-modified cells back into the patient. For beta-thalassemia, sickle cell disease and adrenoleukodystrophy, we insert a functional copy of the target gene into the patient’s hematopoietic stem cells (HSCs), enabling patients to produce proteins that are otherwise missing or dysfunctional as a result of their hereditary disease. In oncology, the gene therapy process targets a different cell type, called T-cells. In this case, genetic sequences are inserted into a patient’s own T-cells to program the T cells to specifically recognize and attack cancer cells. bluebird bio’s approach represents a highly personalized therapy and a potential paradigm shift in the treatment of severe genetic and orphan diseases.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
1992
Size (employees)
328 (est)+30%
Bluebird bio was founded in 1992 and is headquartered in Cambridge, US

Key People at Bluebird bio

Nick Leschly

Nick Leschly

CEO
Jeffrey T. Walsh

Jeffrey T. Walsh

Chief Operating Officer
Mitchell H. Finer

Mitchell H. Finer

Chief Scientific Officer
Richard E. T. Smith

Richard E. T. Smith

Vice President, Investor Relations
Cyrus Mozayeni

Cyrus Mozayeni

Senior Director, Business Development
Linda C. Bain

Linda C. Bain

Vice President, Finance and Business Operations

Bluebird bio Office Locations

Bluebird bio has offices in Cambridge, Paris and Seattle
Cambridge, US (HQ)
150 Second St
Seattle, US
208 1616 Eastlake Ave E
Paris, FR
155 Rue Du Faubourg Saint Denis

Bluebird bio Data and Metrics

Bluebird bio Financial Metrics

Bluebird bio's revenue was reported to be $6.2 m in FY, 2016
Numbers are in $, USD

Revenue (FY, 2016)

6.2 m

Revenue growth (FY, 2015 - FY, 2016), %

(56%)

Net income (FY, 2016)

(263.5 m)

EBIT (FY, 2016)

(267.8 m)

Market capitalization (26-May-2017)

3.2 b

Closing share price (26-May-2017)

79.8

Cash (31-Dec-2016)

278.9 m
Bluebird bio's current market capitalization is $3.2 b.
Numbers are in $, USDFY, 2013Y, 2014Y, 2015FY, 2016

Revenue

20.2 m25.4 m14.1 m6.2 m

Revenue growth, %

26%(45%)(56%)

Operating expense total

45.1 m86 m183.1 m274 m

EBIT

(24.9 m)(60.6 m)(169 m)(267.8 m)

EBIT margin, %

(124%)(238%)(1201%)(4351%)

Interest income

29 k152 k

Pre tax profit

(60.5 m)(166.7 m)(264.1 m)

Income tax expense

(60 k)612 k

Net Income

(25.3 m)(48.7 m)(166.8 m)(263.5 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

206.3 m347.8 m164.3 m278.9 m

Accounts Receivable

Inventories

5 m4.5 m6 m19.8 m

Current Assets

212 m480 m524 m724.2 m

PP&E

10.9 m15.7 m82.6 m157 m

Goodwill

13.1 m13.1 m13.1 m

Total Assets

224.4 m556.7 m1 b1.1 b

Accounts Payable

4.4 m3 m6.3 m13.7 m

Current Liabilities

34.9 m43 m40.4 m74.5 m

Additional Paid-in Capital

250.1 m638.4 m1.2 b1.4 b

Retained Earnings

(98.7 m)(147.4 m)(314.2 m)(577.7 m)

Total Equity

151.7 m491.3 m850.5 m869.4 m

Financial Leverage

1.5 x1.1 x1.2 x1.3 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(25.3 m)(48.7 m)(166.8 m)(263.5 m)

Depreciation and Amortization

941 k4.2 m7.4 m9.6 m

Accounts Receivable

Inventories

(14 m)

Accounts Payable

2.1 m(2.2 m)2.5 m6.7 m

Cash From Operating Activities

43.5 m(59.7 m)(98.4 m)(189.6 m)

Purchases of PP&E

(8.7 m)(8.7 m)(7.1 m)(16 m)

Cash From Investing Activities

(9.8 m)(157.2 m)(571.9 m)62.7 m

Cash From Financing Activities

105.6 m358.5 m486.7 m241.5 m
Y, 2016

Financial Leverage

1.3 x

Bluebird bio Market Value History

Bluebird bio Median Salaries

Source: 16 public H-1B filings from Bluebird bio

Bluebird bio Online and Social Media Presence

Bluebird bio News and Updates

Bluebird bio Company Life and Culture

You may also be interested in